1st Quarter, 2025
Summary
- Rethinking the deployment of AI-disease identification
AI-based disease identification systems have shown exceptional promise. However, the prevailing model—relying on hospital blood data—faces a major barrier: significant variation between hospital datasets (Section 1) - Introducing a New AI Category
To address this challenge, a new class of lab-based Integrated Disease Identification (IDI) systems has emerged. These systems generate standardized blood data internally, bypassing the inconsistency of external hospital sources. - The Breakthrough: 2nd Generation IDI
While others have attempted this, Immune IQ (IIQ) is the first to successfully develop a point-of-care IDI system, combining real-time diagnostics with internally consistent data generation—right at the patient’s side. - Strategic Investment Momentum
IIQ is launching a $90 million venture round in May, already attracting strong interest from top-tier financial and AI-sector investors. (Section 2)
Section 1: A Changing Landscape in AI Disease Identification
A Critical Barrier Becoming Clear
A transformation is underway in patient diagnosis—driven by AI. By analyzing patterns in blood data, AI systems can detect life-threatening illnesses within seconds, often before symptoms appear. This paradigm shift has positioned AI-powered diagnostics as one of healthcare AI’s fastest-growing and most capitalized sectors.
Yet, early investments have focused on hospital-based systems powered primarily by blood data. It has become clear recently that these solutions face a critical barrier: hospital-to-hospital blood data variation. Differences in equipment and processes create variations that make it difficult for AI to recognize reliable disease patterns.
This creates a massive white-space opportunity for next-generation platforms that can standardize inputs and deliver reliable, scalable disease detection.
Enter Integrated Disease Identification (IDI) systems: A Game-Changing Advancement
To solve the inconsistency problem, a new class of systems called Integrated Disease Identification (IDI) has emerged. These systems standardize blood data before AI analysis, enabling precise, repeatable disease detection at scale.
Investment Landscape: Two Generations of IDI Systems
First-Generation IDI
- Companies: Cytovale (launched), Inflammatix (FDA-approved)
- Model: Lab-based, high-cost (~$250/test)
- Advances: High diagnostic accuracy across hospitals by overcoming inter-hospital variation
- Limitations:
- Designed specifically for hospital-based sepsis detection
- Limited scalability due to cost and complexity
- Because of the compelling need to deploy AI-powered disease identification, VCs are heavily funding IDI companies
Second-Generation IDI
- Company: Immune IQ
- Model: Nurse-operated, point-of-care (POC), low-cost (~$20/test)
- Advances:
- Retains first-gen accuracy
- Adds scalability, 5-minute broad disease detection at POC
- Improved clinical workflow integration
- Value Proposition:
- Effective in hospitals, clinics, and developing countries
- Addresses diagnostic needs for the ~50% of global population lacking timely access to diagnostic testing
- Regulatory Path: Expected FDA approval by 2026
Why This Matters – For Investors & the World
For Investors
- Massive Market Potential: Rapid, accurate diagnostics across multiple diseases
- Scalability: Low operational barriers for clinical use
- Regulatory Momentum: Existing FDA approvals validate the model
- Timing: Second-generation system is poised for market entry in the near term
For the World
- Lives Saved: Early detection of heart disease, cancer, sepsis, and more
- Bridging the Diagnostic Gap: Facilitates disease identification in low-resource and rural settings, enabling timely treatment
- Pandemic-Response: Rapid identification = faster containment
- Lower Global Healthcare Costs: Fewer hospitalizations, better-targeted care
By standardizing diagnostics and cutting operational barriers, point-of-care IDI systems are poised to democratize access to advanced healthcare technologies, potentially saving millions of lives annually in regions previously excluded from medical innovation
This is a category-defining moment in diagnostic AI. Second-generation IDI platforms represent a rare opportunity to invest at the intersection of cutting-edge technology, unmet clinical needs, and scalable delivery.
Section 2: Series D Funding
This shift in industry thinking is the perfect backdrop for the launch of IIQ’s $90M Series D round.
- The raise is supported by investment bankers and the biotech development arm of a major AI company.
- Venture capital interest in the IDI space is strong.
- We plan to officially launch our fundraising campaign in May.
If you would like to learn more about our Series D funding, please feel free to contact us.
Section 3: Bridge Financing
Due to complications with a crypto financing vehicle (common in Switzerland, uncommon in US), we were unable to complete an investment with a Swiss family office.
We are now raising an additional $2M in bridge funding—on top of previously secured funds—to move forward with our clinical studies.
Bridge Terms: Conversion into Series D stock at a 25% discount; 12% interest
Interested in participating in the bridge?
This will be the last investment opportunity for individual investors. Feel free to contact us via email (ddeetz@immuneiq.com)to learn more.
Other News and Conclusion
Barbara Roth, IIQ’s COO gave a talk in San Diego Jan. 6th on “Using AI to anticipate instrument failure” and is giving a talk on “Machine-learning-based manufacturing of precison blood testing catridges” at the Connected Manufacturing conference in St. Louis on June 24th
While we’ve made tremendous progress and checked many of the key boxes for a major success, including:
- Delivering a solution that addresses some of the most urgent and high-impact needs in healthcare — notably early sepsis detection and scalable AI deployment
- Overcoming the most significant technical challenges and establishing a streamlined path to commercialization, accelerated by leading strategic partners (see below)
- Earning strong support from both the healthcare community and influential voices on Wall Street
We recognize that true success lies in the details — and there’s still critical work ahead to bring this vision fully to life.
Thank you to our investors and partners for bringing us this far.
